Cannara Biotech Inc.
Cannara Biotech Inc.
Your view on LOVFF
Overview
What the company does, where it operates, and who runs it.
About Cannara Biotech Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zohar Krivorot
- Headquarters
- 333 Decarie Blvd., Saint-Laurent, QC, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zohar Krivorot
- Headquarters
- 333 Decarie Blvd., Saint-Laurent, QC, CA
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Cannara Biotech Inc. from FRC's valuation model, read against the market price. LOVFF last traded at $1.31, 17.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cannara Biotech Inc.. Starting points for Cannara Biotech Inc.: P/E 17.8, EPS $0.11, beta 0.28 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cannara Biotech Inc.. Cannara Biotech Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cannara Biotech Inc.. Trailing twelve-month EPS for Cannara Biotech Inc. stands at $0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current QtrAug 2026 | Next QtrNov 2026 | Current YearFY Aug 2026 | Next YearFY Aug 2027 |
|---|---|---|---|---|
| Avg. estimate | CAD 0.04 | CAD 0.00 | CAD 0.12 | CAD 0.21 |
| Low estimate | CAD 0.04 | CAD 0.00 | CAD 0.12 | CAD 0.20 |
| High estimate | CAD 0.04 | CAD 0.00 | CAD 0.12 | CAD 0.21 |
| No. of analysts | 1 | 0 | 1 | 1 |
| Year-ago EPS | — | CAD 0.01 | CAD 0.14 | — |
| Growth | — | -100.0% | -14.1% | — |
Revenue Estimate
| Revenue | Current QtrAug 2026 | Next QtrNov 2026 | Current YearFY Aug 2026 | Next YearFY Aug 2027 |
|---|---|---|---|---|
| Avg. estimate | CAD 34.64M | CAD 34.90M | CAD 123.69M | CAD 143.60M |
| Low estimate | CAD 33.20M | CAD 33.56M | CAD 122.50M | CAD 140.16M |
| High estimate | CAD 36.01M | CAD 35.92M | CAD 125.31M | CAD 147.07M |
| No. of analysts | 3 | 3 | 4 | 4 |
| Year-ago revenue | — | CAD 30.11M | CAD 107.32M | — |
| Growth | — | +15.9% | +15.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cannara Biotech Inc.. Cannara Biotech Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cannara Biotech Inc. valued side by side against its closest peers. Cannara Biotech Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cannara Biotech Inc.. Coverage tracks Cannara Biotech Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cannara Biotech Inc.